# Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome

> **NCT03440736** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 781 (actual)

## Conditions studied

- Psoriasis
- Metabolic Syndrome

## Interventions

- **DRUG:** Secukinumab
- **BEHAVIORAL:** Life-style intervention

## Key facts

- **NCT ID:** NCT03440736
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-28
- **Primary completion:** 2021-11-30
- **Final completion:** 2022-06-03
- **Target enrollment:** 781 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03440736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03440736, "Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03440736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*